The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras
Therapeutic monoclonal antibody (mAb) development and the processes for manufacturing drug substance have evolved since the first approval of the mAb in 1986. As the past is often the prologue to the future, the history of these technologies has been classified here into three eras, leading to specu...
Saved in:
| Main Author: | Brian Kelley |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2024.2373330 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost and supply considerations for antibody therapeutics
by: Chun Chen, et al.
Published: (2025-12-01) -
Factors Affecting the Ups and Downs of Profit in the Food and Beverage Sub-Sector for the 2021-2023 Period
by: Nurul Aulia Dewi, et al.
Published: (2025-07-01) -
Exosomes in clinical trial and their production in compliance with good manufacturing practice
by: Yu-Shuan Chen, et al.
Published: (2020-01-01) -
Good Manufacturing Practice (GMP) guidelines for virgin olive oil production
by: Christos Petrakis
Published: (1994-04-01) -
The manufacture of AAV for gene therapy applications using a closed, semi-automated hollow-fiber bioreactor
by: Adrien Soula, et al.
Published: (2025-06-01)